Cyxone Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Cyxone hat ein Gesamteigenkapital von SEK34.3M und eine Gesamtverschuldung von SEK0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK38.5M bzw. SEK4.2M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

SEK 0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	SEK 12.29m
Eigenkapital	SEK 34.30m
Gesamtverbindlichkeiten	SEK 4.24m
Gesamtvermögen	SEK 38.54m

Jüngste Berichte zur Finanzlage

Here's Why We're Not Too Worried About Cyxone's (STO:CYXO) Cash Burn Situation

Dec 12

We Think Cyxone (STO:CYXO) Can Afford To Drive Business Growth

Aug 29

Recent updates

Here's Why We're Not Too Worried About Cyxone's (STO:CYXO) Cash Burn Situation

Dec 12

We Think Cyxone (STO:CYXO) Can Afford To Drive Business Growth

Aug 29

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: CYXODie kurzfristigen Aktiva des Unternehmens (SEK12.9M) übersteigen seine kurzfristigen Passiva (SEK4.2M).

Langfristige Verbindlichkeiten: CYXO hat keine langfristigen Verbindlichkeiten.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: CYXO ist schuldenfrei.

Schulden abbauen: CYXO hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: CYXO hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: CYXO hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 2.8% pro Jahr abnimmt

Cyxone Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Here's Why We're Not Too Worried About Cyxone's (STO:CYXO) Cash Burn Situation

We Think Cyxone (STO:CYXO) Can Afford To Drive Business Growth

Recent updates

New major risk - Share price stability

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.062 loss in 1Q 2023)

Cyxone AB (publ) Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Financial position

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Cyxone AB (publ) to Report Q4, 2024 Results on Feb 25, 2025

New major risk - Revenue and earnings growth

Cyxone AB (publ) to Report Q3, 2023 Results on Nov 21, 2023

Cyxone Announces CFO Changes

Cyxone AB (publ) Announces Board Changes

Cyxone AB (Publ) Receives Ethical and Regulatory Approval from Georgia to Conduct Clinical Phase 2B Study in RA

Cyxone AB (Publ) Advances the Patent Portfolio for Rabeximod

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Cyxone AB (Publ) Appoints Carl-Magnus Högerkorp as Permanent CEO

Cyxone (publ) Receives Ethical and Regulatory Approval from Hungary to Start Clinical Phase 2b Study in RA

Price target decreased to kr4.20

Cyxone AB (Publ) Announces That the Members of the Nomination Committee for Annual General Meeting 2023

Cyxone Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (publ) Receives Regulatory Approval to Start Clinical Phase 2B Study in RA

Cyxone AB (Publ) Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (Publ) Announces CFO Changes

Cyxone AB (publ) to Report Q3, 2022 Results on Oct 27, 2023

Cyxone Files Submission to Start Clinical Phase 2B Study in Poland and Georgia

Cyxone Receives Pre-IND Response from the US FDA regarding RA study

Cyxone (Publ) Files Regulatory Submission to Start Clinical Phase 2B Study with Rabeximod

Cyxone Announces Executive Changes

Cyxone AB Announces Promising T20k/Kora Combination Therapy Efficacy in Preclinical Therapeutic Model of MS

Price target increased to kr16.00

Safety Confirmation and Observed Trends in Covid-19 Study Build Further Confidence in Cyxone's Rheumatoid Arthritis Program

Cyxone (publ) Announces Resignation of Cornel Pater as Chief Medical Officer

Cyxone (publ) Reports Publication of Four Patent Applications Pertaining to its Drug Candidate Rabeximod

Cyxone (publ) Initiates Early Operations with Global Contract Research Organization to Conduct Phase 2B Trial in Rheumatoid Arthritis

Here's Why We're Not Too Worried About Cyxone's (STO:CYXO) Cash Burn Situation

Cyxone Files Patent Application with Potential to Extend Market Exclusivity of the Drug Candidate Rabeximod

Cyxone AB (Publ) Comments on the Covid-19 Study Results

Cyxone (Publ) Presents Top-Line Results from A Phase 2 Study of Rabeximod in Covid-19 Patients

Cyxone AB (Publ) Expects to Communicate Top-Line Results from A Recently Concluded Phase 2 Trial of Its Drug Candidate Rabeximod in Covid-19 Patients

We Think Cyxone (STO:CYXO) Can Afford To Drive Business Growth

CFO & Interim CEO Ola Skanung has left the company

Cyxone Announces Rabeximod in Covid-19 Phase 2 Trial Closed and Data to Be Reports in Third Quarter

Cyxone Explores Expanding into New Regions to Mitigate Potential Delay in Covid-19 Trial Completion

Chief Operating Officer has left the company

Cyxone Joins Forces with Leading Rheumatoid Arthritis Expert

Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K

Cyxone AB (publ) to Report Q4, 2021 Results on Feb 11, 2022

Cyxone (publ.) Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod

Cyxone AB (publ), Annual General Meeting, Jun 03, 2021

Cyxone AB (publ) Files an IND in the US with Rabeximod Following Positive Feed-Back from Pre-IND Meeting with the FDA

New 90-day low: kr5.03

Cyxone AB (publ) Files Patent Application to Extend Exclusivity of Rabeximod

New 90-day low: kr5.51

Cyxone Announces Expanded Plans for Rabeximod

New 90-day low: kr5.52

Cyxone AB (Publ) Revises the Development Plan for Rabeximod

New 90-day high - kr7.48

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen